Screener
BridgeBio Pharma BBIO Finite-Lived Intangible Assets, Accumulated Amortization
Finite-Lived Intangible Assets, Accumulated Amortization at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization.
The source filing: BridgeBio Pharma’s 10-Q, filed August 10, 2026.
- Filed
- Aug 10, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001743881-26-000027
| Line item | June 30, 2026 / Weighted-average Estimated Useful Lives | June 30, 2026 / Amount | December 31, 2025 / Weighted-average Estimated Useful Lives | December 31, 2025 / Amount |
|---|---|---|---|---|
| Gross amount | 13.7 years | $39,400 | 13.7 years | $39,400 |
| Less accumulated amortization | (12,759) | (11,323) | ||
| Total | $26,641 | $28,077 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's finite-lived intangible assets, accumulated amortization?
- BridgeBio Pharma (BBIO) reported finite-lived intangible assets, accumulated amortization of $12.76M in Q2 2026.
- What does finite-lived intangible assets, accumulated amortization mean?
- Finite-Lived Intangible Assets, Accumulated Amortization
Ask your AI about BridgeBio Pharma's finite-lived intangible assets, accumulated amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude